La maladie de Parkinson en France (serveur d'exploration) - Merge (Accueil)

Index « Auteurs » - entrée « J L Montastruc »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
J L Monstastruc < J L Montastruc < J L Renard  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 61.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
003539 (2003) G. Fénelon [France] ; S. Giménez-Roldán ; J L Montastruc ; F. Bermejo ; F. Durif ; I. Bourdeix ; J-J Péré ; L. Galiano ; J. SchadrackEfficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.
003798 (2002) O. Rascol [France] ; J J Ferreira ; P. Payoux ; Ch Brefel-Courbon ; J L Montastruc[Management of levodopa-induced dyskinesia].
003B14 (2001) O. Rascol [France] ; J. Ferreira ; J L Montastruc[Abnormal diurnal somnolence, "sleep attacks" and antiparkinson drugs].
003B18 (2001) O. Rascol [France] ; N. Fabre ; C. Brefel-Courbon ; J L MontastrucThe pharmacologic treatment of gait ignition failure.
003B28 (2001) J M Senard [France] ; C. Brefel-Courbon ; O. Rascol ; J L MontastrucOrthostatic hypotension in patients with Parkinson's disease: pathophysiology and management.
003B34 (2001) J L Montastruc [France] ; K. Desboeuf ; M. Lapeyre-Mestre ; J M Senard ; O. Rascol ; C. Brefel-CourbonLong-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease.
003B42 (2001) O. Rascol [France] ; I. Arnulf ; H. Peyro-Saint Paul ; C. Brefel-Courbon ; M. Vidailhet ; C. Thalamas ; A M Bonnet ; S. Descombes ; B. Bejjani ; N. Fabre ; J L Montastruc ; Yves Agid [France]Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.
003B52 (2001) O. Rascol [France] ; J J Ferreira ; C. Thalamas ; M. Galitsky ; J L MontastrucDopamine agonists. Their role in the management of Parkinson's disease.
003E67 (2000) O. Rascol [France] ; J L Montastruc[Role of dopaminergic agonists].
004308 (1999) J L Montastruc [France] ; O. Rascol ; J M SenardTreatment of Parkinson's disease should begin with a dopamine agonist.
004365 (1999) O. Rascol [France] ; C. Brefel-Courbon ; S. Descombes ; J L MontastrucClinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
004378 (1999) J L Montastruc [France] ; M. Ziegler ; O. Rascol ; M. MalbezinA randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease.
004725 (1998) J L Montastruc [France] ; M. Pelat ; P. Verwaerde ; C. Brefel-Courbon ; M A Tran ; O. Blin ; O. Rascol ; J M SenardFluoxetine in orthostatic hypotension of Parkinson's disease: a clinical and experimental pilot study.
004729 (1998) C. Brefel [France] ; C. Thalamas [France] ; S. Rayet [France] ; A. Lopez-Gil ; K. Fitzpatrick ; S. Bullman [Royaume-Uni] ; D R Citerone [Royaume-Uni] ; A C Taylor [Royaume-Uni] ; J L Montastruc [France] ; O. Rascol [France]Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients
004733 (1998) O. Rascol [France] ; U. Sabatini ; C. Brefel ; N. Fabre ; S. Rai ; J M Senard ; P. Celsis ; G. Viallard ; J L Montastruc ; F. CholletCortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.
004996 (1997) O. Rascol [France] ; U. Sabatini ; N. Fabre ; C. Brefel ; I. Loubinoux ; P. Celsis ; J M Senard ; J L Montastruc ; F. CholletThe ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients.
004A25 (1997) J L Montastruc [France] ; O. Rascol ; J M SenardGlutamate antagonists and Parkinson's disease: a review of clinical data.
004D21 (1996) O. Rascol [France] ; A J Lees ; J M Senard ; Z. Pirtosek ; J L Montastruc ; D. FuellRopinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease.
004D26 (1996) J L Montastruc [France] ; O. Rascol ; J M SenardNew directions in the drug treatment of Parkinson's disease.
004D51 (1996) J L Montastruc [France] ; J M Senard ; O. Rascol ; A. RascolAutonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences.
004D55 (1996) M E Llau [France] ; G. Durrieu ; M A Tran ; J M Senard ; O. Rascol ; J L MontastrucA study of dopaminergic sensitivity in Parkinson's disease: comparison in "de novo" and levodopa-treated patients.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/Author.i -k "J L Montastruc" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/Author.i  \
                -Sk "J L Montastruc" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Merge
   |type=    indexItem
   |index=    Author.i
   |clé=    J L Montastruc
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024